glp-1 gip therapies muscle preservation 2025 Optimizing for obesity and diabetes management The possible mechanisms of weight

Available from: Accessed 28 June 2025 Medicines and Healthcare products Regulatory Agency

If you happen to be an elderly individual, the risk of losing muscle mass, frailty, bone health those are real concerns and those are side effects of the medication

Migration inhibitory factor induces killing of Leishmania major by macrophages: dependence on reactive nitrogen intermediates and endogenous TNF-

GLP-1 and GIP are incretin hormones secreted by intestinal epithelial cells following food intake

Since ADA (American Diabetes Association) and FDA confirmed that apart from metformin in Type 2 diabetes management, Glucagon-like peptide-1 analogues give favourable results, especially in contraindication and metformin intolerance patients, so the use of GLP-1 agonists is highly preferred treatment in lower serum glucose levels or hypoglycemia

A medically supervised GLP-1 program allows providers to personalize care, adjust dosing, and monitor progress safely over time